Two healthcare enterprises are scheduled to price their initial public offerings during the week of November 9, 2026, aiming to raise a combined $414.3 million. Boston-based biotech firm Rezera (RZRA) is offering 16.67 million shares priced between $11.00 and $13.00 to raise $200 million for its peripheral artery disease treatments. Meanwhile, Swiss dental products start-up vVardis Holding AG (VVVV), backed by private equity player Apollo, is offering 9.52 million shares in a targeted range of $21.00 to $24.00 to raise approximately $214.29 million for its drill-free cavity repair technology.
Despite the active healthcare slate, Wall Street remains intensely focused on the potential arrival of Anthropic (ANT). Market watchers anticipate that the AI assistant Claude developer could disclose terms for its highly anticipated mega-IPO as early as Tuesday, November 10, 2026. Such a move would position Anthropic’s public offering to officially price the following week, dominating broader investor attention amid the current market activity.
